查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917712

性行为感染传染病（STD）检测市场－2026年至2031年预测

Sexually Transmitted Disease (STD) Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计性行为感染传染病 (STD) 检测市场将从 2025 年的 98.19 亿美元成长到 2031 年的 146.19 亿美元，复合年增长率为 6.86%。

性行为感染传染病（STD）检测市场是全球诊断领域的重要组成部分，且成长迅速，其成长主要受性传染感染疾病持续带来的公共卫生负担所驱动。该市场涵盖多种诊断披衣菌感染和平台，旨在检测导致常见性行为感染传染病的病原体，包括衣原体感染、淋病、梅毒、人类免疫力缺乏病毒（HIV）、人类乳突病毒（HPV）和单纯疱疹病毒（HSV）。全球高感染率、旨在筛检和预防的公共卫生措施不断增加，以及提升检测的可及性、速度和准确性的技术进步，共同推动了市场成长。

推动市场扩张的关键且强有力的因素是全球性行为感染传染病（STI）持续高发。常见细菌性和性行为感染传染病的发生率仍然居高不下，令人担忧，因此对诊断检测的需求持续增加。爱滋病毒仍然是重点关注对象，其持续传播使得广泛检测对于诊断和治疗监测都至关重要。同时，由于行为、社会和医疗保健可近性等多种因素的共同作用，披衣菌感染、淋病和梅毒等感染疾病在许多地区反弹。未经治疗的性行为感染（如不孕症、骨盆腔发炎、某些癌症、不良妊娠结局、爱滋病毒传播风险增加等）造成的严重长期健康后果，凸显了有效诊断解决方案在临床和公共卫生领域的紧迫性。这种流行病学现实决定了对检测服务的根本需求。

为满足这项需求，各国政府和公共机构实施了多项公共卫生倡议，旨在提高公众意识并推广早期疗育筛检干预。国家和地方卫生部门经常进行有针对性的筛检计画、宣传宣传活动和伴侣告知服务，以遏制传播。许多措施专门针对高风险族群，并致力于消除与检测相关的污名。这些项目通常包括提供补贴或免费的检测套组，并将筛检纳入常规初级保健，从而从根本上提高检测量，并将性行为感染检测确立为标准诊疗的一部分，进而推动市场成长。

技术进步是推动市场发展和扩大其覆盖范围的关键驱动力。高灵敏度和高特异性的分子诊断检测技术，特别是核酸增幅检查（NAATs），因其比传统培养方法更高的准确性，已成为检测细菌性行为感染（ STIs，如披衣菌感染和淋病）的黄金标准。家用检测套组的快速成长和日益完善是一大趋势。这些解决方案允许使用者自行采集检体（阴道拭子、尿液、指尖血等）并邮寄至中心实验室，消除了隐私、便利性和社会污名等重大障碍。这种直接面向消费者的模式显着提高了检测的可近性，尤其是在那些不愿前往医疗机构的人群中，也是成长要素。

儘管市场驱动因素强劲，但医疗保健差异和社会污名化仍然构成重大限制。在低收入和中等收入国家以及已开发国家服务不足的地区，由于医疗基础设施匮乏、缺乏训练有素的人员、费用高昂以及人们对性行为感染的预防和症状缺乏了解等因素，获得检测的机会往往受到限制。根深蒂固的性健康问题社会污名化会阻碍人们接受检测，即使检测服务可用。克服这些障碍需要采取多管齐下的方法，结合价格合理的即时诊断技术、社区检测项目和持续的去污名化工作，而这仍然是一项持续的挑战。

从区域来看，北美预计将继续保持领先的市场份额。这一主导地位归功于该地区较高的性行为感染报告发病率、完善的诊断基础设施以及积极主动的公共卫生监测和筛检计画。较高的健康意识、有利的检测报销环境以及众多创新型全球诊断试剂製造商的存在，进一步巩固了该地区的地位。持续进行的公共卫生宣传活动以及先进分子检测技术在临床环境中的广泛应用，共同创造了高频检测的环境。

竞争格局主要由大型多元化诊断公司和专注于分子传染病检查的公司主导。主要参与企业在检测专案的广度、分析性能（灵敏度和特异性）、高通量实验室的产能以及用于简化工作流程的整合自动化平台开发等方面展开竞争。一项关键策略重点是扩展多重检测，以便从单一检体中检测多种病原体，从而提高效率并实现全面筛检。此外，企业也正在大力投资开发和商业化用户友好的CLIA豁免就地检验，以便在非实验室环境下快速获得检测结果，并改进支援居家检测服务的数位平台。

总之，性行为感染检测市场的发展动力源自于亟待满足的公共卫生需求，而技术进步则进一步提升了检测的准确性、可近性和可接受性。全球性行为感染疫情的难以捉摸以及筛检日益融入预防性医疗保健体系，也为其成长提供了结构性支撑。未来市场趋势将受到以下因素的显着影响：居家检测模式的持续普及、面向资源匮乏地区快速低成本照护现场技术的开发，以及为消除污名化和解决性健康保健领域健康差异而持续开展的努力。随着诊断技术的不断发展，它们仍将是遏制并最终减轻全球性行为感染负担的基础。

本报告的主要优势

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业及其他细分市场。
  • 竞争格局：了解全球主要参与企业的策略倡议，并了解透过正确的策略进入市场的潜力。
  • 市场驱动因素与未来趋势：探索市场驱动因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021-2025年实际数据，2026-2031年预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯）、重大发展等。

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依疾病类型分類的性行为感染传染病（STD）检测市场

  • 介绍
  • 披衣菌感染
  • 淋病
  • 单纯疱疹病毒
  • 梅毒
  • 人类乳突病毒（HPV）
  • 其他的

第六章性行为感染传染病（STD）检测市场（依检测地点划分）

  • 介绍
  • 检查室检测
  • 照护现场侦测 (POC)

第七章 各地区性行为感染传染病（STD）检测市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第九章：公司简介

  • Abbott Laboratories
  • Becton Dickinson Company
  • Biomerieux, Inc.
  • Bio-Rad Laboratories Inc.
  • Diasorin Molecular LLC
  • Hologic Inc.
  • Roche Holdings AG
  • Thermo Fisher Scientific（Affymetrix）

第十章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615659

The sexually transmitted disease (STD) testing market is anticipated to increase at a 6.86% CAGR, from USD 9.819 billion in 2025 to USD 14.619 billion in 2031.

The Sexually Transmitted Disease (STD) testing market is a critical and expanding component of the global diagnostics landscape, driven by the persistent public health burden of infectious diseases transmitted through sexual contact. This market encompasses a wide range of diagnostic technologies and platforms designed to detect pathogens responsible for common STDs, including chlamydia, gonorrhea, syphilis, human immunodeficiency virus (HIV), human papillomavirus (HPV), and herpes simplex virus (HSV). The market's growth is propelled by high global infection rates, increasing public health initiatives aimed at screening and prevention, and significant technological evolution that is improving test accessibility, speed, and accuracy.

A primary and powerful driver of market expansion is the sustained high prevalence of STDs worldwide. The incidence of common bacterial and viral infections remains alarmingly high, creating a continuous and growing need for diagnostic testing. HIV continues to be a major focus, with ongoing transmission requiring widespread testing for both diagnosis and monitoring of treatment efficacy. Simultaneously, infections like chlamydia, gonorrhea, and syphilis have seen resurgent rates in many regions, often fueled by a combination of behavioral, social, and healthcare access factors. The serious long-term health consequences of untreated STDs-including infertility, pelvic inflammatory disease, certain cancers, adverse pregnancy outcomes, and enhanced HIV transmission-underscore the clinical and public health imperative for effective diagnostic solutions. This epidemiological reality ensures a foundational demand for testing services.

Complementing this driver are concerted government and institutional public health initiatives aimed at increasing awareness, screening, and early intervention. National and regional health agencies frequently implement targeted screening programs, public awareness campaigns, and partner notification services to curb transmission. Many initiatives specifically focus on high-risk populations and aim to reduce the stigma associated with testing. These programs often involve the provision of subsidized or free testing kits and the integration of screening into routine primary care, thereby structurally increasing testing volumes and fostering market growth by normalizing STD testing as a component of standard healthcare.

Technological advancement is a key force shaping the market's evolution and expanding its reach. The development of highly sensitive and specific molecular diagnostic tests, notably Nucleic Acid Amplification Tests (NAATs), has become the gold standard for detecting bacterial STDs like chlamydia and gonorrhea due to their superior accuracy over traditional culture methods. A significant trend is the rapid growth and refinement of at-home testing kits. These solutions, which often utilize self-collected samples (such as vaginal swabs, urine, or fingerstick blood) mailed to a central lab, address critical barriers related to privacy, convenience, and stigma. This direct-to-consumer model is dramatically increasing testing accessibility, particularly among individuals reluctant to visit a clinic, and represents a major growth vector for the market.

Despite strong drivers, the market faces significant restraints related to healthcare disparities and social stigma. In low- and middle-income countries, as well as underserved communities in developed nations, access to testing is often limited by factors including lack of healthcare infrastructure, shortage of trained personnel, cost, and low health literacy regarding STD prevention and symptoms. Deeply ingrained social stigma surrounding sexual health can deter individuals from seeking testing, even when services are available. Overcoming these barriers requires multifaceted approaches combining affordable point-of-care technologies, community-based testing programs, and sustained destigmatization efforts, which remain ongoing challenges.

Geographically, North America is anticipated to maintain a dominant market share. This prominence is attributed to the region's high reported incidence rates of STDs, a well-established and accessible diagnostic infrastructure, and proactive public health surveillance and screening programs. High levels of health awareness, favorable reimbursement landscapes for laboratory testing, and the presence of leading global diagnostics manufacturers who drive innovation further consolidate the region's position. Continuous public health campaigns and the widespread adoption of advanced molecular testing in clinical practice sustain a high-volume testing environment.

The competitive landscape features large, diversified diagnostics corporations and firms specializing in molecular infectious disease testing. Key players compete on the basis of test menu breadth, analytical performance (sensitivity and specificity), throughput for high-volume laboratories, and the development of integrated, automated platforms that streamline workflow. A major strategic focus is the expansion of multiplex assays that can detect several pathogens from a single sample, improving efficiency and comprehensive screening. Significant investment is also directed toward the development and commercialization of user-friendly, CLIA-waived point-of-care tests that can deliver rapid results in non-laboratory settings, and in refining the digital platforms that support at-home testing services.

In conclusion, the STD testing market is driven by an urgent and unmet public health need, magnified by technological progress that is making testing more accurate, accessible, and acceptable. Its growth is structurally supported by the unrelenting global prevalence of sexually transmitted infections and the increasing integration of screening into preventive healthcare frameworks. The future trajectory of the market will be significantly influenced by the continued penetration of at-home testing models, the development of faster and cheaper point-of-care diagnostics for low-resource settings, and the ongoing battle to reduce stigma and improve health equity in sexual healthcare. As diagnostics continue to evolve, they will remain the cornerstone of efforts to control and ultimately reduce the burden of STDs worldwide.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Sexually Transmitted Disease (STD) Testing Market Segmentation

  • By Disease Type
  • Chlamydia
  • Gonorrhea
  • Herpes Simplex Virus
  • Syphilis
  • Human Papillomavirus (HPV)
  • Others
  • By Testing Location
  • Laboratory Testing
  • Point of Care (POC) Testing
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SEXUALLY TRANSMITTED DISEASE (STD) TESTING MARKET BY DISEASE TYPE

  • 5.1. Introduction
  • 5.2. Chlamydia
  • 5.3. Gonorrhea
  • 5.4. Herpes simplex virus
  • 5.5. Syphilis
  • 5.6. Human papillomavirus (HPV)
  • 5.7. Others

6. SEXUALLY TRANSMITTED DISEASE (STD) TESTING MARKET BY TESTING LOCATION

  • 6.1. Introduction
  • 6.2. Laboratory testing
  • 6.3. Point of care (POC) testing

7. SEXUALLY TRANSMITTED DISEASE (STD) TESTING MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Abbott Laboratories
  • 9.2. Becton Dickinson Company
  • 9.3. Biomerieux, Inc.
  • 9.4. Bio-Rad Laboratories Inc.
  • 9.5. Diasorin Molecular LLC
  • 9.6. Hologic Inc.
  • 9.7. Roche Holdings AG
  • 9.8. Thermo Fisher Scientific (Affymetrix)

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations